Dose – response relationship of bevacizumab in hereditary hemorrhagic telangiectasia

Hereditary hemorrhagic telangiectasia (HHT), a genetic vascular disorder associated with epistaxis and hepatic shunts, is responsible for high-output cardiac failure in rare cases. Bevacizumab, which targets vascular endothelial growth factor, was shown to decrease both cardiac index (CI) and epista...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:MAbs
Päätekijät: Azzopardi, Nicolas, Dupuis-Girod, Sophie, Ternant, David, Fargeton, Anne-Emmanuelle, Ginon, Isabelle, Faure, Frédéric, Decullier, Evelyne, Roux, Adeline, Carette, Marie-France, Gilbert-Dussardier, Brigitte, Hatron, Pierre-Yves, Lacombe, Pascal, Leguy-Seguin, Vanessa, Rivière, Sophie, Corre, Romain, Bailly, Sabine, Paintaud, Gilles
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Taylor & Francis 2015
Aiheet:
Reports
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4622710/
https://ncbi.nlm.nih.gov/pubmed/25751241
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2015.1022693
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia